The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $67.24

Today's change+0.10 +0.15%
Updated February 24 8:00 PM -5GMT. Delayed by at least 15 minutes.
 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $67.24

Today's change+0.10 +0.15%
Updated February 24 8:00 PM -5GMT. Delayed by at least 15 minutes.

Spdr S&P Biotech Etf up (U.S.)$0.10

Spdr S&P Biotech Etf closed up Friday by (U.S.)$0.10 or 0.15% to (U.S.)$67.24. Shares have lost 3.18% over the last five days, but sit 3.83% below their 52-week high. This security has outperformed the S&P 500 by 15.23% during the last year.

Key company metrics

  • Open(U.S.) $66.43
  • Previous close(U.S.) $67.14
  • High(U.S.) $67.42
  • Low(U.S.) $66.30
  • Bid / Ask-- / --
  • YTD % change+13.60%
  • Volume4,834,592
  • Average volume (10-day)4,154,261
  • Average volume (1-month)4,952,629
  • Average volume (3-month)6,266,140
  • 52-week range(U.S.) $46.49 to (U.S.) $69.92
  • Beta1.60
  • Trailing P/E3.69×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.30
  • Dividend yield0.45%
  • Trailing EPS(U.S.) $18.23
Updated February 24 8:00 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+2,202.84%

Based on its net profit margin of 2,202.84%, Spdr S&P Biotech Etf is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX1.57%Sector:FinancialsIndustry:Investment Trusts

Latest Company News

Latest Press Releases

    No Press Release Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q4/2014Q2/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Jun 30, 201406/30/2014Dec 31, 201312/31/2013Jun 30, 201306/30/2013
Revenue81032
Total other revenue--------
Total revenue81032
Gross profit--------
Total cost of revenue--------
Total operating expense2221
Selling / general / administrative2221
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income6811
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax262141200125
Income after tax262141200125
Income tax, total--000
Net income262141200125
Total adjustments to net income--------
Net income before extra. items262141200125
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items262141200125
Inc. avail. to common incl. extra. items262141200125
Diluted net income262141200125
Dilution adjustment--------
Diluted weighted average shares23202327
Diluted EPS excluding extraordinary itemsvalue per share11.217.028.674.61
Dividends per sharevalue per share0.350.320.040.03
Diluted normalized EPSvalue per share11.217.028.674.61